Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.

摘要: Summary Background Clinical predictors including Asian, female, adenocarcinoma and never-smoker epidermal growth factor mutation are associated with gefitinib responsiveness in non-small-cell lung cancer. Direct comparison between clinical EGFR for their predictive power has not been reported. Patients methods For 120 Korean NSCLC patients treated gefitinib, we have analyzed mutational status exons 18, 19 21. were grouped according to the number of (female, never-smoker). Response rate (RR), time-to-progression (TTP) overall survival (OS) analyzed. Multivariate analysis was performed investigate which approach yielded better prediction. Results RRs 0: 3.4%, 1: 17.1%, 2: 29.4% 3: 33.3% ( p =0.002). gefitinib-sensitive showed 61.9% RR compared 12.1% remaining Conclusion should be whenever possible effective prediction objective benefit from one or more predictors.